Please assess the completion status of the following clinical trial:

Trial Title: Effects of Pennsaid on Clinical Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject will be between 18 and 80 years of age.~2. Subject has not been on Pennsaid or other topical non-steroid anti-inflammatory drugs for at least one month.~3. Subject agrees to make no change in his/her current pain medications during the entire study period. This requirement will ensure that valid comparisons of primary and secondary measures can be made before and after the study.~4. Subject has a VAS pain score of 4 or above at the beginning of the study.~5. Subject has had a neuropathic pain condition such as those listed above for at least three months. This requirement is to avoid clinical uncertainty from an unstable pain condition and to minimize the study variation.~6. Female subjects of childbearing age must have a negative urine pregnancy test at the initial visit.~Exclusion Criteria:~1. Subject has documented severe liver or renal disease that will affect the elimination of Pennsaid or is subject to the adverse effect of Pennsaid on these organs. (Renal dysfunction is defined as eGFR \< 60. Hepatic dysfunction is defined as LFTs ≥ 3X ULN.)~2. Subject has pending litigation related to the neuropathic pain condition.~3. Subject has active skin lesion or open wound at the site of Pennsaid application (e.g., active shingles with skin lesions).~4. Subject is pregnant or lactating.~5. Subject has scar tissue or sensory deficit at the site of QST.~6. Subject is allergic to diclofenac or has cross-sensitivity to other non-steroid anti-inflammatory drugs.~7. Subject has a positive urine (illicit) drug test.~8. Subjects who experience asthma, urticaria or an allergic type reaction when taking aspirin or NSAIDs.~9. Subjects undergoing coronary artery bypass surgery.~10. Subject with a known history of cardiovascular disease, ulcer, gastrointestinal bleed or impaired renal function.~11. Subjects currently using NSAIDS.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Pennsaid Phase I (Type: ACTIVE_COMPARATOR): Pennsaid (20-40 drops; 2-4 times daily) Upon completion of the first phase, subjects in each arm will be crossed over (i.e., from placebo to Pennsaid and vise versa). Pennsaid or placebo lotion will be packed in a container with identical appearance before being dispensed to study subjects.
- Placebo Phase I (Type: PLACEBO_COMPARATOR): Study subject will topically apply placebo lotion (20-40 drops) 2-4 times daily to the painful area for the next two weeks. The dose titration will be based on the size of painful area (approximately 10 drops for every 4 square inches). Subjects will be asked to fill in a daily pain diary and report any side effects to the research center. A phone number and a beeper number will be provided to subjects.

Based on this trial design, predict the completion outcome and termination type (if applicable).